
AC220

产品编号: D51008

CAS: 950769-58-1

分子式: C₂₉H₃₄Cl₂N₆O₄S

纯度: ≥98%

InChi: InChi=1S/C₂₉H₃₂N₆O₄S.2ClH/c1-29(2,3)25-17-26(33-39-25)32-27(36)30-20-6-4-19(5-7-20)22-18-35-23-9-8-21(16-24(23)40-28(35)31-22)38-15-12-34-10-13-37-14-11-34;;/h4-9,16-18H,10-15H2,1-3H3,(H2,30,32,33,36);2*1H

InChi Key: DHYPGRVMIOATAE-UHFFFAOYSA-N

Smiles: Cl.Cl.CC(C)(C)C1=CC(NC(=O)NC2C=CC(=CC=2)C2=CN3C(=N2)SC2C=C(C=CC3=2)OCCN2CCOCC2)=NO1

外观: 固体粉末

作用通路: Apoptosis

溶解性: DMSO: ≥33 mg/mL

保存条件: Store in dry, dark place for one year.

产品介绍: Quizartinib, also known as AC220 and AC010220, is an orally available FLT3 / STK1 inhibitor with potential antineoplastic activity. Class III receptor tyrosine kinase inhibitor AC220 selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs), resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis. Mutations in FLT3, resulting in constitutive activation, are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases.